ArticleStem cell research & therapy2025
Elimination of CDX2 restricts intestinal hybrid differentiation signatures in stem cell-derived hepatocyte-like cells.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe generation of functionally mature hepatocytes from human induced pluripotent stem cells (iPSC) has the potential to replace primary human hepatocytes (PHH) as the gold standard in vitro model for drug screening, studies of hepatotoxicity as well as liver disease, and is considered a gateway technology to future cell therapy applications. However, we recently reported that current protocols for deriving hepatocyte-like cells (HLC) from iPSC fail to restrict differentiation to the hepatic lineage. Instead, single cell transcriptomics and protein expression analysis uncovered that current methods induce hybrid differentiation, leading to the establishment of abundant hepatic and intestinal gene expression signatures within individual HLC, thereby compromising hepatocyte functionality and phenotype.
methodsDifferentiation of iPSC to HLC was performed and followed by analysis of transcriptome changes during iPSC to HLC differentiation in comparison to PHH. Differentiation pattern clustering (DiPaC) of differentially expressed genes (DEG) and downstream bioinformatic analysis identified the gene regulatory networks (GRN) involved in establishing hybrid differentiation signatures in HLC, indicating a major influence of caudal-domain type 2 (CDX2) in HLC-IEC hybrid differentiation. CRISPR Cas9-based genetic engineering was used to generate CDX2 RESULTS AND
conclusionTranscriptome analysis of WT iPSC to HLC differentiation in comparison to PHH confirmed the establishment of intestinal differentiation gene expression signatures in HLC and indicated a major role of CDX2 in erroneous lineage decision making of HLC. Absence of CDX2 during iPSC to HLC differentiation promoted hepatic specification through the induction of HHEX and PROX1, while drastically reducing intestinal differentiation signatures. CDX2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.